26 01, 2024

TAmiRNA ‘2023 In Review’

2024-01-26T11:44:38+01:00January 26th, 2024|biomarker, biomarkers, exosomes, extracellular vesicle, ISO 13485, Liver disease, microRNA, microRNA services, microRNAs, quality, sequencing, smallRNA|Comments Off on TAmiRNA ‘2023 In Review’

One last look back at 2023 before we turn our attention to our goals for 2024: last year brought us progress in many areas, from the development of new laboratory and data analyses to the implementation of hepatomiR® in routine clinical diagnostics and the establishment of important partnerships. Our thanks go to the entire (growing) TAmiRNA team, and our customers and partners! We look forward to working together and to our joint successes in 2024!

26 05, 2022

hepatomiR kit

2023-03-10T10:14:05+01:00May 26th, 2022|biomarkers, hepatomiR kit, Liver disease, microRNA|Comments Off on hepatomiR kit

TAmiRNA has launched its latest hepatomiR® CE-IVD testing kit that can measure levels of three important liver-enriched microRNAs (liver miRNAs) in human blood to determine a patient’s liver function. TAmiRNA’s microRNA-based hepatomiR® kit is worldwide the first approved CE-IVD test to measure microRNA liver biomarkers in human plasma. The new microRNA-based hepatomiR® technology represents a milestone previously restricted to research use only (RUO) testing. click here for more Information on the hepatomiR-kit

6 10, 2020

MedUni Wien “Researcher of the Month” Oktober 2020

2023-03-10T10:53:18+01:00October 6th, 2020|biomarker, Liver disease, microRNAs, Personalized medicine|Comments Off on MedUni Wien “Researcher of the Month” Oktober 2020

We want to congratulate Dr. Patrick Starlinger to his award “Researcher of the Month” for his work in cooperation with TAmiRNA GmbH, in Hepatology. "Predicting Postoperative Liver Dysfunction Based on Blood Derived MicroRNA Signatures." Hepatology. 2019 Jun;69(6):2636-2651. Click here for more information on TAmiRNA services Click here to read the story

30 03, 2019

Predicting Postoperative Liver Dysfunction Based on Blood Derived MicroRNA Signatures.

2023-03-10T10:57:11+01:00March 30th, 2019|biomarker, Liver disease, microRNAs, Personalized medicine|1 Comment

We want to draw your attention to the latest publication of the Department of Surgery, Medical University of Vienna, in cooperation with TAmiRNA GmbH, in Hepatology. "Predicting Postoperative Liver Dysfunction Based on Blood Derived MicroRNA Signatures." Hepatology. 2019 Jun;69(6):2636-2651. Personalized medicine in liver surgery. Together with colleagues from Medical University Vienna we could show that plasma levels of three miRNAs can accurately predict liver dysfunction prior to surgery. This will allow us to stratify patients into risk groups that need preoperative liver volume augmentation or might even be better off with alternative treatment options. Click here to read the study

Go to Top